Eevia Health

1. Annual report and results

The Annual General Meeting adopted the income statement and the balance sheet for the financial year 2022 and resolved that the net loss of 2 042 616,03 EUR – shall be transferred to retained earnings/loss account. No dividends are to be paid.

2. Discharge from Liability

The Annual General Meeting granted the Members of the Board of Directors and the Chief Executive Officer discharge from liability for the management of the Company’s business for the financial year 2022.

3. Election of the Members of the Board of Directors

The Annual General Meeting resolved, for the time until the end of the next Annual General Meeting, to re-elect Martin Bjørklund, Per Benjaminsen and Oskar Wegelius, and elect Patricia Wiklund, as Members of the Board of Directors. Martin Bjørklund was elected as the Chairman of the Board of Directors. Magne Ruus Simensen and Johanna Panula were not re-elected, and the Company thank them for their service.

4. Remuneration to the Board of Directors

The Annual General Meeting resolved that the Chairman shall receive remuneration of EUR 20,000 and that every other Board Member shall receive remuneration of EUR 10,000.

5. Election and remuneration of the Auditor

The Annual General Meeting resolved to elect KPMG as auditor, with Mari Kaasalainen (Authorized Public Accountant, KHT) as the principal auditor.  It was resolved that the auditor shall receive remuneration according to the approved invoice.

6. Authorizing the Board of Directors to decide on the issuance of shares, options, and other special rights

The Annual General Meeting resolved to authorize the Board of Directors to decide, in one or more transactions, on the issuance of shares and the issuance of options and other special rights entitling to shares referred to in Chapter 10 Section 1 of the Companies Act as follows:

The number of shares to be issued based on the authorization may in total amount to a maximum of 10 000 000 shares. The authorization will be used for growth financing and management incentive options. The Board of Directors decides on all other terms and conditions of the issuances of shares and options and other special rights entitling to shares. The issuance of shares and options and other special rights entitling to shares may be carried out in deviation from the shareholders’ pre-emptive rights (directed issue) if there is a weighty financial reason for the company. The authorization is valid until 29 June 2033.

For more information, please contact:

Stein Ulve, CEO

Email: stein.ulve@eeviaheath.com

Phone: +358 400 22 5967

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia’s other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.

To learn more, please visit  www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.